PHAT Insider Trading Activity and SEC Form 4 Filings
PHAT insider trading summary
No open-market insider purchases or sales of Phathom Pharmaceuticals, Inc. (PHAT) have been reported on SEC Form 4 in the past 12 months.
Latest PHAT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 3, 2025 | Robert Charles Breedlove | Principal Accounting Officer | Sell | $7K (524 @ $13.51) |
| Sep 5, 2025 | Robert Charles Breedlove | Principal Accounting Officer | Sell | $6K (461 @ $12.09) |
| Jul 16, 2025 | Robert Charles Breedlove | Principal Accounting Officer | Sell | $14K (1,692 @ $8.36) |
| May 21, 2025 | James N Topper | Insider | Buy | $15K (3,780 @ $3.86) |
| May 14, 2025 | James N Topper | Insider | Buy | $21K (6,300 @ $3.32) |
| May 13, 2025 | James N Topper | Insider | Buy | $4K (1,120 @ $3.16) |
| May 12, 2025 | James N Topper | Insider | Buy | $38K (12,601 @ $3.04) |
| May 9, 2025 | James N Topper | Insider | Buy | $107K (33,376 @ $3.19) |
| May 9, 2025 | James N Topper | Insider | Buy | $8K (2,226 @ $3.62) |
| May 7, 2025 | Asit Parikh | Insider | Buy | $12K (5,000 @ $2.40) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.